Document:

SHAREHOLDERS' AGREEMENT

     Shareholders'  Agreement ("Shareholders' Agreement"), dated as of April 15,
2003  by  and among NeoGenomics, Inc., a Nevada corporation having its principal
offices  at  1726  Medical  Blvd.,  Suite 101, Naples, FL 34110 (the "Company"),
Michael  Dent ("Dr. Dent"), MVP 3, LP, a limited partnership organized under the
laws  of  Delaware  ("MVP"),  John  Elliot,  Steven  Jones,  and  Larry  Kuhnert
(collectively,  the  "Individual Investors").   Dr. Dent, MVP and the Individual
Investors  may  be  referred  to  herein  individually  as  a  "Shareholder" and
collectively  as  the  "Shareholders."
                                        .
                              W I T N E S S E T H:

     WHEREAS,  the  Shareholders  own  shares  (the  "Shares") of the issued and
outstanding common stock, par value $0.001 per share (the "Common Stock") of the
Company  in  the amounts set forth opposite their names on Schedule "A" attached
to  this  Agreement;

     WHEREAS,  MVP, the Company and NeoGenomics, Inc., a Florida corporation and
a  wholly  owned  subsidiary  of  the  Company, are entering into a certain Loan
Agreement,  dated  as  of  April  15,  2003  (the  "Loan  Agreement");  and

     WHEREAS,  the  Company  and  Shareholders  believe  it  to be in their best
interests  to  provide  for  the  continuity  of  management and policies of the
Company  by  imposing certain restrictions and obligations on themselves and the
outstanding  Shares  of  the  Company.

NOW,  THEREFORE,  in  consideration  of the mutual promises herein set forth and
subject  to  the  terms  and  conditions  hereof,  the parties agree as follows:

                                    ARTICLE I
                  MANAGEMENT OF THE COMPANY AND RELATED MATTERS

     1.1     Management  and  Operation  of the Company.  The responsibility for
             -------------------------------------------
the  overall  management and operations of the Company shall be entrusted to its
Board  of  Directors  (the  "Board").  The  Company  shall  be  administered  in
accordance with the purposes of this Agreement and in accordance with the bylaws
of  the  Company  and  the  laws  of  the  State  of  Nevada.

     1.2     Board  of  Directors.
             ---------------------

          1.2.1     Composition  of  Board.  The  Shareholders agree that during
                    ----------------------
the  Term  of this Agreement the Board of Directors of the Company shall consist
of  no more than seven (7) members and that the initial Board of Directors shall
be  as  follows  until such time as new members shall be elected or appointed to
the  Board  of  Directors  in  accordance  with  this  Agreement:

     Michael  T.  Dent,  M.D.
     Kevin  J.  Lindheim

The  Board of Directors shall hold their positions until the next annual meeting
of  Shareholders.  The  Shareholders  and the Company further agree that at each
meeting  of Shareholders, the Company's Board of Directors shall be nominated by
the  Company  and  elected  by  the  Shareholders  in accordance with the terms,
conditions,  and  provisions  of  Section  1.2.2  below.

          1.2.2     Election  of  the Board of Directors. At each annual meeting
                    ------------------------------------
of  shareholders  or  any  special  meeting  of  shareholders  called  to  elect
Directors,  Dr.  Dent,  MVP  and  the  Individual  Investors agree to vote their
respective  Shares  (whether  now  owned  or  hereinafter  acquired) at all such
meetings  of  the  shareholders  or  pursuant  to  any written action or consent
without  a meeting so that the Company's Board of Directors shall, at all times,
consist  of  members  who  shall  be  nominated  and  elected  as  follows:

          (i)  The Dent Director.  Dr. Dent shall have the right to nominate and
               -----------------
elect  one  (1)  director  (the  "Dent  Director")  to  the  Company's  Board of
Directors.  The  right of Dr. Dent to appoint the Dent Director will expire upon
the  earlier  of:  (i) Dr. Dent's resignation as an officer of the Company; (ii)
the  termination  of  Dr.  Dent's  employment  for  cause  (as  set forth in his
Employment  Agreement); or (iii) the sale by Dr. Dent of more than fifty percent
(50%)  of  the  Shares  he  holds  as  of  the  date  of  this  Agreement.

          (ii) The MVP Directors. MVP shall have the right to nominate and elect
               -----------------
four  (4)  directors  (the "MVP Directors") to the Company's Board of Directors.

          (iii)  The  Independent  Directors.   MVP  and Dr. Dent shall mutually
                 ---------------------------
agree  upon  two  non-employee directors (the "Independent Directors") and shall
appoint  such  individuals  to  the  Company's  Board  of  Directors.

     1.2.3     Non-voting Observers.     At any time that no MVP Director serves
               --------------------
on  the Company's Board of Directors, MVP shall be entitled to appoint up to two
(2)  non-voting  observers to the Board, and such observers shall be entitled to
notice  of  and attendance at all Board meetings, advance copies of all consents
provided  to  directors  for  execution,  and  access  to  all  information made
available  to  the  Board.  Such observers shall incur no liability as directors
for  serving  in  their  capacity  as  non-voting  observers, but shall in their
capacity  as non-voting observers be eligible for indemnification by the Company
to  the  same  extent  as  any  Board member.  MVP shall be entitled to appoint,
re-appoint,  remove,  replace,  and  fill  any  vacancy  arising from the death,
disability,  resignation,  or  removal  by  the  MVP  of any such observer.  The
Company  shall  not  have the right to remove any such observer, but the Company
shall  be entitled to request that MVP replace any observer that the Company, in
good  faith,  believes  improperly  impairs  the function of the Board, to which
request  MVP  shall  give  due  consideration.

     1.2.4     Term;  etc. Dr. Dent, MVP and the Individual Investors shall vote
               ----------
their  respective  shares  of  stock  for  the persons nominated as directors in
accordance  with  this  Section  1.2  and  who  otherwise meet the standards for
qualification  set  forth  herein;  provided that, notwithstanding anything else
contained herein, the Shareholders shall not be required to vote their shares in
favor  of,  and  shall be entitled to remove, any director nominee who has:  (i)
been  convicted  of, or entered a plea of guilty or nolo contendere to, a felony
or  misdemeanor  involving  fraud,  embezzlement,  theft  or dishonesty or other
criminal  conduct  against  Company,  (ii)  has died or been judicially declared
incompetent  or  of  unsound  mind,  (iii)  unexcused  absences  from  three (3)
consecutive  Board meetings or (iv) been terminated "for cause" (as such term is
defined  therein)  pursuant  to  any  written employment agreement or consulting
agreement  between  such  director  and  the Company. Each person nominated as a
director  must  be  at  least  twenty-one (21) years of age. All directors shall
serve  for  one  (1)  year  terms, or until their earlier death, resignation, or
removal or until re-elected at any annual or special meeting of the Shareholders
in  accordance  with  the foregoing procedures and requirements of this Section.
Any  director  of the Company may be removed with or without cause, at any time,
by  majority vote (or written action) of the Shareholder group who nominated and
elected such director.  Any vacancy on the Board of Directors shall be filled by
the  Shareholder  group  who  nominated  and  elected  such director through the
holding  of a special meeting of Shareholders or pursuant to a written action or
consent  in  lieu  of  a  special  meeting.

     1.3     Officers.  The  Board shall appoint such officers of the Company as
             ---------
may be prescribed by the Company's bylaws.  It is agreed by the parties that the
initial  officer  of  the  Company  shall  be:

               Name                                Titles
               ----                                ------

               Michael  T.  Dent,  M.D.          Chief  Executive  Officer  and
                                                  Secretary

The  officers  of the Company shall have such powers and duties as prescribed by
the  Board  and  the  Company's  bylaws and, if applicable, as set forth in such
officer's  employment  agreement  with  the  Company.

          1.4     Capitalization.    The  Company  represents  that  the current
                  --------------
capitalization  of  the  Company  is  as  follows:

          (a)     Common  Stock:  There  are  currently  one  hundred  million
                  -------------
(100,000,000)  authorized  shares of Common Stock, par value $.001 per share, of
which  18,409,416  shares  are  issued  and  outstanding.

          (b)     On  a Fully-Diluted Basis:  Except for (i) 40,000 shares which
                  -------------------------
the  Company  intends  to  issue  to Technology Capital Group, Inc., (ii) 20,000
shares  which the Company intends to issue to its Scientific Advisory Board, and
(iii)  an  option  to  acquire 100,000 shares at the market price on the date of
issuance,  which  the  Company  intends  to  issue  to  a member of its Board of
Directors,  there  are  not outstanding any options, warrants, rights (including
conversion  or preemptive rights), or agreements for the purchase or acquisition
from  the  Company  or, to the knowledge of the Company from any shareholder, of
any  shares  of  the  capital  stock  of  the  Company.

                                   ARTICLE II
                RESTRICTIONS ON SHAREHOLDERS' TRANSFERS OF SHARES

     2.1     Restrictions  on  Sales  of  Stock  by  Shareholders
             ----------------------------------------------------
(a)  Subject  to  Section  2.1(b),  the  Shareholders  shall  not  sell, assign,
transfer, convey or otherwise dispose of (a "Sale") any of their Shares, whether
now  owned  or hereafter acquired, unless they have complied with the provisions
of  Section  2.2  hereof  (in  the  case  of  Dr.  Dent) and then, to the extent
applicable,  with  the  provisions  of  Sections  2.3  and/or  2.4  hereof.
     (b)  Any  Sale  or attempted Sale of Stock in violation of any provision of
this  Agreement shall be void, and the Company shall not record such Sale on its
books or treat any purported transferee of such Stock as the owner of such Stock
for  any  purpose.
     2.2     Rights  of First Offer.   Subject to Section 2.2(f), in addition to
             ----------------------
and  not in limitation of any other restrictions on Sales of Shares contained in
this  Agreement,  any  Sale  of  Stock  by Dr. Dent shall be consummated only in
accordance  with  the  following  procedures:
(a)  Dr.  Dent shall first deliver to the Company and the Individual Investors a
written  notice  (a  "RFR  Offer  Notice"),  which  shall  (i)  state Dr. Dent's
                      ------------------
intention  to  sell Shares to one or more persons, the amount and type of Shares
to  be sold (the "Subject Shares"), the purchase price therefor and a summary of
                  --------------
the other material terms of the proposed Sale and (ii) offer the Company and the
Individual  Investors  the  option  to  acquire all or a portion of such Subject
Shares  upon the terms and subject to the conditions of the proposed Sale as set
forth  in  the  RFR Offer Notice (the "RFR Offer"), provided that such RFR Offer
                                       ---------
may provide that it must be accepted by the Company and the Individual Investors
(in  the  aggregate)  on an all or nothing basis (an "All or Nothing Sale"). The
                                                      -------------------
RFR  Offer  shall  remain  open  and irrevocable for the periods set forth below
(and,  to  the  extent  the RFR Offer is accepted during such periods, until the
consummation  of the Sale contemplated by the RFR Offer). The Company shall have
the  right  and  option, for a period of 15 days after delivery of the RFR Offer
Notice  (the  "Company RFR Acceptance Period"), to accept all or any part of the
               -----------------------------
Subject  Shares  at  the purchase price and on the terms stated in the RFR Offer
Notice,  provided  that  the  Company  may  accept  less than all of the Subject
Shares,  in  an All or Nothing Sale, only if all of the remaining Subject Shares
is  accepted  by  the  Individual  Investors as set forth below. Such acceptance
shall  be  made  by  delivering  a written notice to Dr. Dent and to each of the
Individual  Investors  within  the  Company  RFR  Acceptance  Period.
(b)  If  the  Company shall fail to accept all of the Subject Shares offered for
Sale  pursuant  to, or shall reject in writing, the RFR Offer (the Company being
required  to  notify in writing Dr. Dent and each of the Individual Investors of
its  rejection  or  failure  to accept in the event of the same), then, upon the
earlier  of the expiration of the Company RFR Acceptance Period or the giving of
such written notice of rejection or failure to accept such offer by the Company,
each  Investor  shall  have  the  right  and  option,  for  a  period of 30 days
thereafter  (the "Individual Investors RFR Acceptance Period"), to accept all or
                  ------------------------------------------
any  part  of the Subject Shares so offered and not accepted by the Company (the
"Refused  Stock") at the purchase price and on the terms stated in the RFR Offer
 --------------
Notice; provided, however, that, if the RFR Offer contemplated an All or Nothing
        -----------------
Sale,  the  Individual  Investors,  in  the  aggregate,  may  accept, during the
Investor  RFR  Acceptance  Period,  all,  but  not less than all, of the Refused
Stock,  at  the  purchase price and on the terms stated in the RFR Offer Notice.
Such  acceptance shall be made by delivering a written notice to the Company and
Dr.  Dent  within  the Individual Investors RFR Acceptance Period specifying the
maximum number of shares such Investor will purchase (the "First Offer Shares").
                                                           ------------------
If,  upon  the expiration of the Individual Investors RFR Acceptance Period, the
aggregate  amount of First Offer Shares exceeds the amount of Refused Stock, the
Refused Stock shall be allocated among the Individual Investors in proportion to
their  ownership  of  the  Company's  capital  stock  on  a fully diluted basis.
     (c)  If  effective  acceptance  shall  not be received pursuant to Sections
2.2(a)  and/or 2.2(b) above, within the periods specified above, with respect to
all  of  the  Subject  Shares offered for Sale pursuant to the RFR Offer Notice,
then  Dr. Dent may sell all or any portion of the Shares so offered for Sale and
not  so  accepted (or, in the case of an All or Nothing Sale, all of the Subject
Shares  offered  for sale pursuant to the RFR Offer Notice), at a price not less
than  the  price,  and on terms not more favorable to the purchaser thereof than
the  terms,  stated in the RFR Offer Notice at any time within 90 days after the
expiration  of  the  Individual  Investors  RFR  Acceptance  Period  (the  "Sale
                                                                            ----
Period").  To  the  extent  Dr.  Dent  Sells all or any portion of the Shares so
offered  for  Sale  during  the  Sale Period, Dr. Dent shall promptly notify the
Company,  and  the Company shall promptly notify the Individual Investors, as to
(i)  the  number  of Shares, if any, that Dr. Dent then owns, (ii) the number of
Shares that Dr. Dent has sold, (iii) the terms of such Sale and (iv) the name of
the  owner(s)  of any shares of Shares sold. In the event that all of the Shares
are  not  sold by Dr. Dent during the Sale Period, the right of Dr. Dent to sell
such  unsold Stock shall expire and the obligations of this Section 2.2 shall be
reinstated.
(d)  All  Sales of Subject Shares to the Company and/or the Individual Investors
subject  to  any  one RFR Offer Notice shall be consummated contemporaneously at
the  offices  of  the  Company on a mutually satisfactory business day within 30
days  after  the expiration of the Company RFR Acceptance Period or the Investor
RFR  Acceptance  Period,  as  applicable, or such other time and/or place as the
parties  to  such  Sales  may  agree.  The  delivery  of  certificates  or other
instruments  evidencing  such Subject Shares duly endorsed for transfer shall be
made on such date against payment of the purchase price for such Subject Shares.
(e) Anything contained herein to the contrary notwithstanding, prior to any Sale
of  Shares  by  Dr.  Dent  pursuant  to  this Section 2.2, Dr. Dent shall, after
complying with the provisions of this Section 2.2, comply with the provisions of
Sections  2.3  and  2.4  hereof,  in  each  case  as  applicable.
     (f)  Notwithstanding the provisions of Sections 2.2(a), (b) and (c), in the
event  that  Dr. Dent shall propose to sell his Shares pursuant to provisions of
Rule  144,  Dr.  Dent  shall  first  deliver  to  the Company and the Individual
Investors,  a  written notice (a "RFR Offer Notice"), which shall (1) state that
Dr.  Dent  intends  to sell Shares pursuant to Rule 144, including the number of
shares proposed to be sold (the "Subject Shares") and (ii) offer the Company and
the  Individual  Investors  the option to acquire all or any portion of any such
Shares  at  the market price for the Shares on the date of such notice (the "RFR
Offer").  The  RFR  Offer  shall remain open and irrevocable for the periods set
forth  below.  The  Company  shall have the right and option for a period of ten
days  after  delivery  of the RFR Offer Notice, to accept all or any part of the
Subject  Shares  at  the purchase price described in the RFR Offer Notice.  Such
acceptance shall be made by delivering written notice to Dr. Dent and to each of
the  Individual Investors within the required period.  If the Company shall fail
to  accept all of the Subject Shares offered for sale pursuant to the RFR Offer,
then  upon  the  expiration  of the Company's acceptance period, each Individual
Investor  shall  have the right and option, for a period of ten days thereafter,
to  accept  all or any part of the Subject Shares so offered and not accepted by
the  Company  at  the  purchase  price  described in the RFR Offer Notice.  Such
acceptance  shall  be  made  by delivering written notice to the Company and Dr.
Dent  within  the  required  period specifying the maximum number of shares each
such  shareholder  desires  to  purchase.  If,  the  number  of available shares
exceeds  the number available, the available number shall be allocated among the
Individual  Investors  in proportion of their ownership of the Company's capital
stock  on a fully diluted basis.  If the Company and the Individual Investors do
not agree to purchase all of the Subject Shares offered for sale pursuant to the
RFR  Offer Notice within the time periods set forth above, Dr. Dent may sell all
or  any  portion  of  the Subject Shares not purchased into the existing current
public  market,  at  such  price  as  he may receive in the public market, for a
period  of 90 days after the expiration of the Individual Investor's rights.  To
the  extent  Dr.  Dent  sells all or any portion of the Subject Shares, Dr. Dent
shall  promptly  notify  the  Company  and the Company shall promptly notify the
Individual  Investors as to the number of Subject Shares which Dr. Dent has sold
pursuant to this provision.  In the event that all of the Subject Shares are not
sold  by  Dr. Dent during this 90 day period, the right of Dr. Dent to sell such
unsold  Shares  shall  expire  and  the obligations of this Section 2.2 shall be
reinstated  as  to  such  Shares.

     2.3     Right  of  Co-Sale.
             ------------------

          (a)     If  any Shareholder (an "RCS Selling Shareholder") proposes to
sell  any Shares ("Co-Sale Shares") to a party or group (a "Co-Sale Transferee")
in  a  transaction  or  series  of related transactions resulting in the Co-Sale
Transferee for the first time controlling the power to vote more than 25% of the
total  votes for nominees to the Board, such RCS Selling Shareholder shall first
give  reasonable  notice  in  reasonable  detail  to  each  other Shareholder in
sufficient  time  to  allow each other Shareholder to participate in the sale on
the  same  terms  and conditions as such RCS Selling Shareholder.  To the extent
any  prospective  Co-Sale  Transferee(s)  refuses  to  purchase  shares or other
securities  from  a  Shareholder exercising its rights of co-sale hereunder, the
RCS Selling Shareholder shall not sell to such prospective Co-Sale Transferee(s)
any  co-Sale  Shares  unless  and  until, simultaneously with such sale, the RCS
Selling  Shareholder  shall purchase the offered shares or other securities from
the other Shareholder.  Notwithstanding the foregoing, this Section 2.2(a) shall
not  apply to (i) any pledge of Co-Sale Shares made pursuant to a bona fide loan
transaction  that  creates  a  mere  security interest; (ii) any transfer to the
ancestors, descendants or spouse or to trusts for the benefit of such persons of
a  transferring  Shareholder;  (iii)  any  bona  fide  gift;  provided  that the
transferring  Shareholder  shall  inform  the other Shareholders of such pledge,
transfer  or  gift prior to effecting it; or (iv) any sale of Shares pursuant to
Rule  144.  Such  transferred  Co-Sale  Shares  will  remain  "Co-Sale  Shares"
hereunder, and such pledgee, transferee or donee shall be bound by the terms and
provisions  of  this  Agreement.

     2.4     Drag-Along  Rights.
             ------------------

     (a)     If  at  any  time the Shareholders holding fifty percent or more of
the  Company's  then  outstanding  shares  of  capital  stock  (the "DAR Selling
Shareholders(s)")  shall  propose  to undertake a sale of fifty percent (50%) or
more  of the Company's then issued and outstanding shares of capital stock to an
unaffiliated  third  party or group in a single transaction or series of related
transactions (a "Proposed Drag-Along Transaction"), then each Shareholder shall,
if  requested by such DAR Selling Shareholder(s), sell all of its Shares in such
transaction  on  the  same terms and for the same per Share consideration.  Such
DAR  Selling  Shareholder(s)  shall  give  each other Shareholder written notice
("Drag-Along  Notice")  of  any  Proposed Drag-Along Transaction at least twenty
(20)  days prior to the date on which such Proposed Drag-Along Transaction shall
be  consummated, including the terms and conditions thereof, and each such other
Shareholder  shall have the obligation to sell its Shares on such same terms and
conditions  in  accordance  with  the  instructions set forth in such Drag-Along
Notice.  In  such event, each Shareholder shall deliver the Share certificate(s)
(accompanied  by duly executed stock powers or other instrument of transfer duly
endorsed  in  blank)  representing  the  Shares  to  the  Company or to an agent
designated  by  the  Company for the purpose of effectuating the transfer of the
Shares  to  the  purchaser  and  the  disbursement  of  the  proceeds  of  such
transactions  to  the  Shareholder(s).

     (b)     Without  limiting  the  generality  of  the  foregoing,  if the DAR
Shareholders  approve  a  sale  (an "Approved Sale") structured as a merger or a
consolidation  or a sale of assets, then each Shareholder shall, if requested by
the  Company  (i)  vote for, consent to and/or not raise objections against such
Approved  Sale,  (ii) waive (to the extent applicable) any dissenters, appraisal
rights or similar rights in connection with a merger or consolidation, and (iii)
take  all necessary and desirable actions in connection with the consummation of
the  Approved  Sale  as  reasonably requested by the Company, including, without
limitation,  exercising  any  warrants  or  conversion  privileges.

          (c)     Any  Shareholder required by the provisions of this Article II
to  transfer  Shares  shall  not  be  required  to  make any representations and
warranties  in connection with such transfer or sale except as to good title and
the  absence  of  liens  with  respect  to  such  Shares, the corporate or other
existence  of  the  Shareholder  and  the  authority, form, validity and binding
effect  of,  and  the  absence  of any conflicts under the charter documents and
material  agreements  of such Shareholder. No such Shareholder shall be required
to  provide  any  indemnity  in  connection  with  such Approved Sale except for
indemnities  for  damages  resulting  from  a  breach  of  the  above-stated
representations  and  warranties.

<PAGE>
                                   ARTICLE III
                  RESTRICTIONS ON COMPANY'S ISSUANCE OF SHARES

     3.1.     Preemptive  Rights.
              ------------------
     (a)     The  Company hereby grants to each Shareholder, for a period of two
(2)  years  from  the date hereof, a preemptive right to purchase, on a pro rata
basis  and  at  the same price and upon the same terms as any other investors at
such  time,  all  or any part of any New Securities (as defined below) which the
Company  may,  from time to time, propose to sell and issue subject to the terms
and conditions set forth below.  A Shareholder's pro rata share, for purposes of
this  subsection  (a),  shall  equal  a  fraction, the numerator of which is the
number  of  shares  of  Common  Stock  then  held  by  such  Shareholder  on  a
fully-diluted  basis, and the denominator of which is the total number of shares
of  Shares  then  held  by  all  of  the  Shareholders on a fully-diluted basis.
     (b)     "New  Securities"  shall  mean  any  capital  stock  of the Company
              ---------------
whether  now  authorized  or  not  and  rights,  options or warrants to purchase
capital  stock,  and securities of any type whatsoever which are, or may become,
convertible  into  capital  stock;  provided,  however,  that  the  term  "New
Securities"  shall  expressly  not  include (i) securities offered to the public
pursuant  to  a  Public  Offering; (ii) securities issued for the acquisition of
another  corporation by the Company by merger, purchase of substantially all the
assets of such corporation or other reorganization resulting in the ownership by
the  Company of not less than 51% of the voting power of such corporation; (iii)
Common  Stock  issued  to  employees or consultants of the Company pursuant to a
stock  option plan, employee stock purchase plan, restricted stock plan or other
employee  stock  plan  or  agreement  approved  by the Board of Directors of the
Company  (provided  that  the total number of shares to be issued under all such
plans  does not exceed 10% of the Company's shares outstanding as of the date of
this Agreement); or (iv) securities issued as a result of any stock split, stock
dividend  or reclassification of Common Stock, distributable on a pro rata basis
to  all  holders  of  Common  Stock.
     (c)     If  the Company intends to issue New Securities, it shall give each
Shareholder  ten (10) days written notice of such intention, describing the type
of  New  Securities  to  be issued, the price thereof and the general terms upon
which the Company proposes to effect such issuance.  Each Shareholder shall have
thirty  (30)  days  (the  "Exercise Period") from the date of any such notice to
agree  to  exercise its preemptive right by giving written notice to the Company
stating  the  quantity  of  New Securities to be so purchased.  Each Shareholder
shall  have  a  right  of  overallotment  such  that if any Shareholder fails to
exercise  his  or  its  preemptive  right  hereunder, the other Shareholders may
purchase  such  portion  on  a  pro  rata basis, by giving written notice to the
Company  within  ten  (10)  days from the date that the Company provides written
notice to the other Shareholders of the amount of New Securities with respect to
which  such  nonpurchasing  Shareholder  has failed to exercise its or his right
hereunder.
[  ]
     {  }(d)     If  any  Shareholder  or  Shareholders  fail  to  exercise  the
foregoing  preemptive  right  with  respect  to  any  New  Securities within the
Exercise  Period (or the additional ten day period provided for overallotments),
the  Company may thereafter sell any or all of such New Securities not agreed to
be  purchased  by  the  Shareholders,  at a price and upon general terms no more
favorable  to  the purchasers thereof than specified in the notice given to each
Shareholder  pursuant  to paragraph (c) above.  In the event the Company has not
sold such New Securities within a ninety (90) day period following expiration of
the  Exercise  Period,  the  Company  shall not thereafter issue or sell any New
Securities without first offering such New Securities to the Shareholders in the
manner  provided  above.

                                   ARTICLE IV
                                 OTHER COVENANTS

     4.1     Dealings  with  Affiliates.  The  Company and its subsidiaries will
             --------------------------
not  enter  into any transaction with MVP, the Individual Investors, Dr. Dent or
their  affiliates,  or  any  other  officer  or  director  of the Company or its
subsidiaries,  or  any  member  of  their  respective  immediate families or any
corporation  or other entity directly or indirectly controlled by one or more of
such  persons  or  members  of their immediate families, except for transactions
made  for  valid business purposes on terms and conditions which the independent
directors  of  the  Company  conclude  are  reasonable  and  arm's  length.

     4.2     Indemnification.
             ----------------

          (a)  The  Company  agrees that, except as may be limited by applicable
law,  for  six  years  from  and  after  the  date  of  this  Agreement,  the
indemnification  obligations set forth in the Company's bylaws as of the date of
this  Agreement,  will  not  be  amended,  repealed or otherwise modified in any
manner  that would adversely affect the rights thereunder of the individuals who
on  or  at  any  time  prior  to  the  date  of  this Agreement were entitled to
indemnification  thereunder  with respect to matters occurring prior to the date
of  this  Agreement.

          (b) In addition to, and not in lieu of the forgoing, the Company shall
indemnify, defend and hold harmless all officers and directors of the Company as
of  the date of this Agreement (the "Indemnified Parties") to the fullest extent
permitted by applicable law and in the bylaws of the Company, as in effect as of
the  date  hereof,  from and against all liabilities, costs, expenses and claims
(including,  without  limitation  reasonable legal fees and disbursements, which
shall be paid, reimbursed or advanced by the Company in a manner consistent with
the  applicable provisions of the Company's bylaws) arising out of actions taken
prior  to the date of this Agreement in performance of their duties as directors
and officers of the Company, in connection with the transactions contemplated by
this  Agreement,  which may be asserted against the Indemnified Parties from and
after  the date of this Agreement, provided, however, that the Company shall not
have the obligation hereunder to any Indemnified Party if the indemnification of
such  Indemnified Party in the manner contemplated hereby is determined pursuant
to a final non-appealable judgment rendered by a court of competent jurisdiction
to  be  prohibited  by  applicable  law.

                                    ARTICLE V
                                  MISCELLANEOUS

     5.1.     Specific  Performance.  Since it is impossible to measure in money
              ---------------------
the  damages which would accrue by reason of a party's failure to perform any of
its  or  his  obligations  under  this Agreement.  It is agreed that the parties
hereto  would  be  irreparably damaged in the event that this Agreement were not
specifically enforced.  Should, therefore, any dispute arise concerning the sale
or  disposition  of any Shares, an injunction may be issued restraining the sale
or  disposition of such Shares pending the termination of such controversy.  The
purchase or sale of any Shares shall also be enforceable by a decree of specific
performance.  Such  remedies shall not be exclusive, but shall be in addition to
any  other  rights  or  remedies which the parties may have at law or in equity.

     5.2.     Termination.  This  Agreement  shall  automatically terminate upon
              -----------
the  occurrence  of  any  one  of  the  following  events:

          (a)     Cessation  of  the  Company's  business;

          (b)     Bankruptcy,  receivership,  or  dissolution  of  the  Company;

     (c)     Voluntary  agreement  in  writing among the Company and each of the
Shareholders;  or

     (d)     The  Company's  completion  of  a  public  offering  of  its equity
securities  in which the gross proceeds to the Company are at least $10,000,000.

     5.3     Legend.  Each  Shareholder  and  the  Company shall take all action
             ------
necessary  (including  exchanging  with  the  Company  certificates representing
Shares  issued  prior to the date hereof) to cause each certificate representing
outstanding  Shares  to  bear  a  legend  containing  the  following  words:
"THE  SECURITIES  REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
THE  SECURITIES  ACT  OF 1933, AS AMENDED. THE SECURITIES HAVE BEEN ACQUIRED FOR
INVESTMENT  AND  MAY  NOT  BE  OFFERED, SOLD, PLEDGED, EXCHANGED, TRANSFERRED OR
OTHERWISE  DISPOSED  OF  UNLESS (A) REGISTERED UNDER SUCH ACT AND ANY APPLICABLE
STATE  SECURITIES  AND "BLUE SKY" LAWS OR (B) AN OPINION OF COUNSEL SATISFACTORY
TO NEOGENOMICS, INC. (THE "COMPANY") THAT SUCH REGISTRATION IS NOT NECESSARY HAS
BEEN  DELIVERED  TO  THE  COMPANY.
IN  ADDITION,  THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE
PROVISIONS  SET  FORTH IN THE SHAREHOLDERS' AGREEMENT DATED AS OF ______________
BY THE COMPANY AND THE PARTIES THERETO, A COPY OF WHICH IS ON FILE IN THE OFFICE
OF  THE  COMPANY."

     5.4.     Notices.     Any  and all notices or other communications required
              -------
or  permitted to be given hereunder shall be given in writing by certified mail,
return  receipt requested, addressed in the case of the Company to its principal
office,  and  in the case of a Shareholder to his address appearing on the stock
books  of  the  Company  and,  if  to  the Individual Investors, with a copy to:

     MEMBRADO  MONTELL,  LLP
     535  West  34th  Street,  2nd  Floor
     New  York,  New  York  10001
     Phone:  (646)  792-2255
     Telecopier  No.:  (646)  792-2258
     Attn.:     Scott  Montell

     5.5.     Partial  Invalidity.  If  any  portion  of this Agreement shall be
              -------------------
ruled  or  adjudicated  invalid  for  any  reason, that por-tion shall be deemed
excised  here  from  and  the remainder of this Agreement shall continue in full
force  and  effect  unaffected  by  any  such  invalidity.

     5.6.     Benefit  and Binding Effect.  This Agreement shall be binding upon
              ---------------------------
and shall inure to the benefit of the parties hereto and their respective heirs,
legal  representatives, successors and assigns.  In the event that a Shareholder
transfers  any  of  its  Shares  to  a third party, then, as a condition to such
transfer,  the  third party shall enter into a counterpart of this Agreement and
shall  have  all  of  the  rights,  and  be  subject  to  all  of the duties and
restrictions  of  a  Shareholder under this Agreement, provided, however, that a
transferee  will  not  become  a  party to this Agreement, nor be subject to the
duties and restrictions imposed on the Shareholders under this Agreement, if the
transferee  acquires  the  Shares  in  any  of  the  following  transfers:

(a)       a  sale  of  any  Shares  pursuant  to  Rule  144;

(b)       a  sale  pursuant  to  Section  2.4.;  or

(c)     an  offering  registered  under  the Securities Act of 1933, as amended.

Notwithstanding anything to the contrary contained in this Agreement, during the
period between the date of this Agreement and April 14, 2005, Dr. Dent shall not
transfer  in  excess of 500,000 Shares during any calendar year, unless (i) as a
condition  to  such  transfer,  the  third  party  receiving shares in excess of
500,000  during  any  such  calendar year shall enter into a counterpart of this
Agreement  and shall have all of the rights, and be subject to all of the duties
and restrictions of a Shareholder under this Agreement, or (ii) such transfer is
made  pursuant  to  Section  2.3  (Right  of  Co-Sale)  hereof.

     5.7.     Counterparts.  This  Agreement  may  be executed simultaneously in
              ------------
two  or  more counterparts, each of which shall be deemed to be an original, and
it  shall  not  be  necessary  in  making  proof of this Agreement to produce or
account  for  more  than  one  such  counterpart.

     5.8.     Governing  Law.  The  corporate  laws of the State of Nevada shall
              --------------
govern  all  issues  concerning  the  relative  rights  of  the  Company and its
shareholders.  All  other  questions  concerning  the  construction,  validity,
enforcement  and  interpretation  of  this  Agreement  shall  be governed by the
internal  laws  of  the State of Florida, without giving effect to any choice of
law or conflict of law provision or rule (whether of the State of Florida or any
other  jurisdictions)  that  would  cause  the  application  of  the laws of any
jurisdictions  other  than  the  State  Florida.  Each  party hereby irrevocably
submits to the jurisdiction of the Circuit Court for Collier County, Florida and
the  United  States  District  Court for the Middle District of Florida, for the
adjudication  of  any  dispute  hereunder  or in connection herewith or with any
transaction  contemplated  hereby  or  discussed  herein, and hereby irrevocably
waives,  and  agrees  not to assert in any suit, action or proceeding, any claim
that  it  is  not personally subject to the jurisdiction of any such court, that
such  suit, action or proceeding is brought in an inconvenient forum or that the
venue  of  such  suit,  action  or  proceeding  is  improper.  EACH PARTY HEREBY
IRREVOCABLY  WAIVES  ANY  RIGHT  IT  MAY HAVE, AND AGREES NOT TO REQUEST, A JURY
TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR
ARISING  OUT  OF  THIS  AGREEMENT  OR  ANY  TRANSACTION  CONTEMPLATED  HEREBY.

     5.9     Entire Agreement.  Each party hereto acknowledges that it or he has
             ----------------
read  this  Agreement,  understands it, and agrees to be bound by its terms, and
further  acknowledges and agrees that it is the complete and exclusive statement
of  the  agreement and understanding of the parties regarding the subject matter
hereof,  which  supersedes  and  merges  all  prior  proposals,  agreements  and
understandings,  oral  and written, relating to the subject matter hereof.  This
Agreement  may not be changed orally, but only by an agreement in writing signed
by  the  party  against  whom  enforcement  of any waiver, change, modification,
extension  or  discharge  is  sought.

<PAGE>
     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first  above  written.

                                   NEOGENOMICS,  INC.

                                   By:____________________________
                                  Name:
                                  Title:    President

                                 MVP  3,  LP,  A  DELAWARE  LIMITED  PARTNERSHIP

                                  BY:  MEDICAL  VENTURE  PARTNERS,  LLC,
                                  A  DELAWARE  LIMITED LIABILITY
                                  COMPANY,  ITS  GENERAL  PARTNER

                                   By:____________________________
                                  Name:
                                  Title:

                                      _______________________________
                                        Michael  T.  Dent,  M.D.

                                   _______________________________
                                        John  Elliot

                                   _______________________________
                                        Steven  Jones

                                   _______________________________
                                        Larry  Kuhnert

<PAGE>
                                   SCHEDULE A
                               OWNERSHIP OF SHARES

NAME             NUMBER  OF  SHARES     %  OF  FULLY  DILUTED  OUTSTANDING
----             ------------------     ----------------------------------
MVP  3,  LP      9,303,279                        50.1%
John  Elliot     1,541,261                         8.3%
Steven  Jones    1,541,261                         8.3%
Larry  Kuhnert   1,541,261                         8.3%
Michael  Dent    2,490,634                        13.4%REGISTRATION RIGHTS AGREEMENT

     This Registration Rights Agreement (this "Agreement") is made this 15th day
of  April,  2003, by NEOGENOMICS, INC., a Nevada corporation (the "Company") for
the  benefit  of  MVP  3,  LP,  a  Delaware limited partnership, John Elliot, an
individual,  Steven  Jones,  an individual, and Larry Kuhnert, an individual and
Michael  T.  Dent,  M.D.,  an  individual  (individually  a  "Shareholder"  and
collectively,  the  "Shareholders").

                                   BACKGROUND

     Pursuant  to  certain  other  agreements  between  the  Company  and  the
Shareholders,  the  Company  has  agreed  to  grant  to the Shareholders certain
registration  rights,  as  more  fully  set  forth  in  this  Agreement.

     NOW  THEREFORE,  in  consideration  of  the  foregoing,  and other good and
valuable  consideration,  the  receipt  and  sufficiency  of  which  is  hereby
acknowledged,  the  parties  hereby  agree  as  follows:

     1.Registration  Rights.
       --------------------

     1.1  Certain  Definitions.  As  used in this Agreement, the following terms
          --------------------
shall  have  the  following  respective  meanings:

     (a)  "Commission"  shall mean the Securities and Exchange Commission or any
other  federal  agency  at  the  time  administering  the  Securities  Act.

     (b)  "Common  Stock"  shall  mean  the  common  stock, par value $0.001 per
share,  of  the  Company.

     (c)  "Form  S-1,  Form  SB-1,  Form S-2, Form SB-2 and Form S-3" shall mean
Form  S-1, Form SB-1, Form S-2, Form SB-2 or Form S-3, respectively, promulgated
by  the  Commission  or  any  substantially  similar  form  then  in  effect.

     (d)  The  terms  "Register",  "Registered"  and  "Registration"  refer to a
registration  effected  by  preparing  and  filing  a  Registration Statement in
compliance  with  the  Securities  Act,  and  the declaration or ordering of the
effectiveness  of  such  Registration  Statement.

     (e)  "Registrable  Securities" shall mean the Shares so long as such shares
are  ineligible  for  sale  under  subparagraph  (k)  of  Rule  144.

     (f)  "Registration  Expenses"  shall  mean  all  expenses  incurred  by the
Company  in complying with Section 2, including, without limitation, all federal
and  state  registration, qualification and filing fees, printing expenses, fees
and  disbursements  of  counsel for the Company, blue sky fees and expenses, the
expense  of  any special audits incident to or required by any such Registration
and  the  reasonable  fees  and  disbursements  of  counsel  for  the  Selling
Shareholders,  as  selling  shareholders.

     (g)  "Registration  Statement"  shall  mean  Form S-1, Form SB-1, Form S-2,
Form  SB-2  or  Form  S-3,  whichever  is  applicable.

     (h)  "Restriction  Termination  Date"  shall  mean,  with  respect  to  any
Registrable  Securities,  the  earliest  of  (i)  the date that such Registrable
Securities  shall  have  been  Registered  and  sold or otherwise disposed of in
accordance  with  the  intended  method of distribution by the seller or sellers
thereof  set  forth  in  the  Registration Statement covering such securities or
transferred  in  compliance  with Rule 144, and (ii) the date that an opinion of
counsel to the Company containing reasonable assumptions (which opinion shall be
subject to the reasonable approval of counsel to any affected Shareholder) shall
have  been  rendered to the effect that the restrictive legend on the Shares can
be  properly  removed  and  such  legend  shall  have  been  removed.

     (i)  "Rule  144" shall mean Rule 144 promulgated by the Commission pursuant
to  the  Securities  Act.

     (j)  "Shareholders"  shall  mean,  collectively,  the  Shareholders,  their
assignees and transferees, and individually, a Shareholder and any transferee or
assignee  of  such  Shareholder.

     (k)  "Securities  Act"  shall  mean the Securities Act of 1933, as amended.

     (l)  "Selling  Expenses"  shall mean all underwriting discounts and selling
commissions  applicable  to  the sale of Registrable Securities pursuant to this
Agreement.

     (m)  "Selling  Shareholders"  shall mean a holder of Registrable Securities
who  requests  Registration  under  Section  2  herein.

     (n)  "Shares"  shall  mean  the  Common  Stock issuable to the Shareholders
pursuant  to  the  Stock  Purchase  Agreements.

     1.2  Required  Registration.  If  the Company shall be requested by holders
          ----------------------
of at least 10% of the total Registrable Securities outstanding that the Company
register  all  or  part  of  such Shareholders' Registrable Securities, then the
Company  shall  promptly,  but  in  no  event later than ten (10) days after its
receipt  of  such  request, give written notice of such proposed Registration to
all  Shareholders, and thereupon the Company shall promptly use its best efforts
to  effect  the  Registration of the Registrable Securities that the Company has
been  requested  to Register for disposition as described in the request of such
holders of Shares and in any response received from any of the holders of Shares
within  ten (10) days or such longer period as shall be set forth in the notice,
after  the  giving of the written notice by the Company; provided, however, that
the  Company  shall  not  be  obligated  to  effect  any  Registration except in
accordance  with  the  following  provisions:

     (a)  The  Company  shall  not  be  obligated  to  file  and cause to become
effective  more  than  three  (3)  registration  statement  in which Registrable
Securities  are Registered pursuant to this Section 1.2; provided, however, that
the  registration  of Registrable Securities on a Form S-3 or any successor form
where  the gross proceeds from the sale of such securities are anticipated to be
at  least  $250,000  shall  not  be  counted towards such three (3) registration
statement  limit.

     (b)  Notwithstanding  the  foregoing,  the Company may include in each such
Registration  requested pursuant to this Section 1.2 any authorized but unissued
shares  of  Common Stock (or authorized treasury shares) for sale by the Company
or  any  issued  and  outstanding  shares  of  Common  Stock for sale by others,
provided,  however,  that,  if  the number of shares of Common Stock so included
pursuant  to  this  clause  (b)  exceeds  the  number  of Registrable Securities
requested  by  the  holders  of  Shares  requesting such Registration, then such
Registration  shall  be  deemed  to  be  a  Registration in accordance, with and
pursuant  to  Section  1.3; and provided further, however, that the inclusion of
such previously authorized but unissued shares of Common Stock by the Company or
issued  and  outstanding  shares  of Common Stock by others in such Registration
shall  not  prevent  the  holders  of  Shares  requesting such Registration from
registering  the  entire  number  of  Registrable  Securities requested by them.

     (c)  The  Company  shall  not  be required to file a registration statement
pursuant  to  this  Section  1:  (i)  within  six  (6)  months  after  any other
registration  by  the  Company (other than under "Excluded Forms," as defined in
Section  1.3  (a)  below)  or  (ii)  for  six  (6)  months after the request for
registration  under  this  Section  1.2  if  the  Company  is  then  engaged  in
negotiations  regarding  a  material  transaction  which  has not otherwise been
publicly  disclosed,  or such shorter period ending on the date, whichever first
occurs,  that  such transaction is publicly disclosed, abandoned or consummated.

     1.3  Piggyback  Registration.
          ------------------------

     (a)  Each  time  that  the  Company  proposes to Register a public offering
solely  of  its Common Stock, other than pursuant to a Registration Statement on
Form  S-4  or  Form  S-8  or similar or successor forms (collectively, "Excluded
Forms"),  the  Company  shall  promptly  give  written  notice  of such proposed
Registration  to all holders of Shares, which shall offer such holders the right
to request inclusion of any Registrable Securities in the proposed Registration.

     (b)  Each  holder  of Shares shall have ten (10) days or such longer period
as  shall  be set forth in the notice from the receipt of such notice to deliver
to  the Company a written request specifying the number of shares of Registrable
Securities  such  holder  intends  to  sell  and  the  holder's intended plan of
disposition.

     (c)  In  the  event  that  the  proposed Registration by the Company is, in
whole  or in part, an underwritten public offering of securities of the Company,
any  request under Section 1.3(b) may specify that the Registrable Securities be
included  in  the underwriting on the same terms and conditions as the shares of
Common  Stock,  if  any,  otherwise  being  sold through underwriters under such
Registration.

          (d)  Upon receipt of a written request pursuant to Section 1.3(b), the
Company  shall  promptly  use  its  best  efforts  to cause all such Registrable
Securities  to  be  Registered,  to  the  extent  required  to  permit  sale  or
disposition  as  set  forth  in  the  written  request.

          (e)  Notwithstanding  the foregoing, if the managing underwriter of an
underwritten  public  offering,  determines  and  advises  in  writing  that the
inclusion  of  all  Registrable  Securities  proposed  to  be  included  in  the
underwritten  public  offering,  together  with any other issued and outstanding
shares of Common Stock proposed to be included therein by holders other than the
holders  of  Registrable  Securities (such other shares hereinafter collectively
referred  to  as  the  "Other  Shares"),  would  interfere  with  the successful
marketing  of  the securities proposed to be included in the underwritten public
offering,  then  the  number  of such shares to be included in such underwritten
public  offering  shall  be  reduced,  and  shares  shall  be excluded from such
underwritten  public  offering  in  a  number  deemed necessary by such managing
underwriter,  first  by  excluding  shares  held  by  the  directors,  officers,
employees  and  founders  of  the Company, and then, to the extent necessary, by
excluding  Registrable  Securities  participating  in  such  underwritten public
offering, pro rata, based on the number of shares of Registrable Securities each
such  holder  proposed  to  include.

     (f)  All  Shares  that are not included in the underwritten public offering
shall  be  withheld  from the market by the holders thereof for a period, not to
exceed  6  months  following  a  public  offering, that the managing underwriter
reasonably  determines  as  necessary in order to effect the underwritten public
offering.  The  holders  of  such Shares shall execute such documentation as the
managing  underwriter  reasonably  requests  to  evidence  this  lock-up.

     1.4  Preparation  and  Filing.  If  and  whenever  the  Company is under an
          ------------------------
obligation  pursuant to the provisions of this Section 1 to use its best efforts
to  effect the Registration of any Registrable Securities, the Company shall, as
expeditiously  as  practicable:

     (a)  prepare  and  file  with  the Commission a Registration Statement with
respect  to  such  Registrable Securities and use its best efforts to cause such
Registration Statement to become and remain effective in accordance with Section
1.4(b)  hereof,  keeping  each Selling Shareholder advised as to the initiation,
progress  and  completion  of  the  Registration;

     (b)  prepare  and  file with the Commission such amendments and supplements
to  such Registration Statements and the prospectus used in connection therewith
as  may  be  necessary  to  keep  such Registration Statement effective for nine
months  and  to comply with the provisions of the Securities Act with respect to
the  sale  or  other  disposition  of all Registrable Securities covered by such
registration  statement;

     (c)  furnish  to  each  Selling  Shareholder  such  number of copies of any
summary  prospectus  or other prospectus, including a preliminary prospectus, in
conformity with the requirements of the Securities Act, and such other documents
as  such  Selling  Shareholder may reasonably request in order to facilitate the
public  sale  or  other  disposition  of  such  Registrable  Securities;

     (d)  use its best efforts to register or qualify the Registrable Securities
covered  by such registration statement under the securities or blue sky laws of
such  jurisdictions  as each Selling Shareholder shall reasonably request and do
any  and  all other acts or things which may be necessary or advisable to enable
such  holder  to  consummate  the  public  sale  or  other  disposition  in such
jurisdictions  of  such  Registrable  Securities;  provided,  however,  that the
Company  shall not be required to consent to general service of process, qualify
to do business as a foreign corporation where it would not be otherwise required
to  qualify  or  submit  to  liability  for state or local taxes where it is not
liable  for  such  taxes;  and

     (e)  at  any  time when a prospectus covered by such Registration Statement
is  required  to  be  delivered  under the Securities Act within the appropriate
period  mentioned  in  Section 1.4(b) hereof, notify each Selling Shareholder of
the  happening of any event as a result of which the prospectus included in such
Registration, as then in effect, includes an untrue statement of a material fact
or  omits to state a material fact required to be stated therein or necessary to
make  the  statements  therein  not misleading in the light of the circumstances
then  existing  and, at the request of such seller, prepare, file and furnish to
such  seller a reasonable number of copies of a supplement to or an amendment of
such  prospectus  as  may  be  necessary so that, as thereafter delivered to the
Shareholders  of  such  shares,  such  prospectus  shall  not  include an untrue
statement  of  a  material  fact or omit to state a material fact required to be
stated  therein or necessary to make the statement therein not misleading in the
light  of  the  circumstances  then  existing.

     1.5  Expenses.  The Company shall pay all Registration Expenses incurred by
          --------
the  Company  in  complying  with  this  Section  1; provided, however, that all
underwriting  discounts  and  selling  commissions applicable to the Registrable
Securities  covered  by  registrations  effected  pursuant to Section 1.2 hereof
shall  be borne by the seller or sellers thereof, in proportion to the number of
Registrable  Securities  sold  by  such  seller  or  sellers.

     1.6  Information  Furnished  by  Shareholder.  It  shall  be  a  condition
          ---------------------------------------
precedent  to  the  Company's obligations under this Agreement as to any Selling
Shareholder that each Selling Shareholder furnish to the Company in writing such
information  regarding such Selling Shareholder and the distribution proposed by
such  Selling  Shareholder  as  the  Company  may  reasonably  request.

     1.7  Indemnification.
          ---------------

          1.7.1  Company's  Indemnification  of Shareholders.  The Company shall
                 -------------------------------------------
indemnify  each  Selling  Shareholder,  each  of  its  officers,  directors  and
constituent  partners, and each person controlling such Selling Shareholder, and
each  underwriter  thereof,  if  any,  and  each  of  its  officers,  directors,
constituent partners, and each person who controls such underwriter, against all
claims,  losses, damages or liabilities (or actions in respect thereof) suffered
or  incurred  by  any  of  them,  to  the extent such claims, losses, damages or
liabilities  arise  out  of  or  are based upon any untrue statement (or alleged
untrue  statement) of a material fact contained in any prospectus or any related
Registration  Statement  incident  to any such Registration, or any omission (or
alleged omission) to state therein a material fact required to be stated therein
or  necessary to make the statements therein not misleading, or any violation by
the  Company  of  any  rule  or  regulation promulgated under the Securities Act
applicable  to  the  Company and relating to actions or inaction required of the
Company in connection with any such Registration; and the Company will reimburse
each  such  Selling  Shareholder, each such underwriter, each of their officers,
directors and constituent partners and each person who controls any such Selling
Shareholder  or  underwriter, for any legal and any other expenses as reasonably
incurred  in  connection  with  investigating or defending any such claim, loss,
damage,  liability or action; provided, however, that the indemnity contained in
this  Section  1.7.1  shall  not apply to amounts paid in settlement of any such
claim,  loss,  damage, liability or action if settlement is effected without the
consent  of  the  Company (such consent shall not unreasonably be withheld); and
provided,  however,  that the Company will not be liable in any such case to the
extent  that any such claim, loss, damage, liability or expense arises out of or
is  based  upon  any untrue statement or omission based upon written information
furnished  to  the Company by such Selling Shareholder, underwriter, controlling
person  or  other indemnified person and stated to be for use in connection with
the  offering  of  securities  of  the  Company.

          1.7.2  Selling  Shareholder's Indemnification of Company. Each Selling
                 -------------------------------------------------
Shareholder  shall  indemnify  the  Company, each of its directors and officers,
each  underwriter,  if any, of the Company's Registrable Securities covered by a
Registration  Statement each person who controls the Company or such underwriter
within  the  meaning  of  the Securities Act and each other Selling Shareholder,
each  of  its  officers,  directors  and  constituent  partners  and each person
controlling  such other Selling Shareholder, against all claims, losses, damages
and  liabilities  (or actions in respect thereof) suffered or incurred by any of
them  and  arising  out of or based upon any untrue statement (or alleged untrue
statement)  of  a  material  fact  contained  in  such Registration Statement or
related  prospectus,  or  any  omission (or alleged omission) to state therein a
material  fact required to be stated therein or necessary to make the statements
therein not misleading, or any violation by such Selling Shareholder of any rule
or  regulation  promulgated  under the Securities Act applicable to such Selling
Shareholder  and  relating  to  actions  or  inaction  required  of such Selling
Shareholder  in  connection  with the Registration of the Registrable Securities
pursuant  to  such  Registration Statement; and will reimburse the Company, such
other  Selling  Shareholders,  such  directors,  officers,  partners,  persons,
underwriters  and  controlling  persons  for  any  legal  and any other expenses
reasonably  incurred  in  connection  with  investigating  or defending any such
claim, loss, damage, liability or action; such indemnification and reimbursement
shall  be  to the extent, but only to the extent, that such untrue statement (or
alleged  untrue  statement)  or  omission  (or alleged omission) is made in such
Registration  Statement  or  prospectus  in reliance upon and in conformity with
written  information  furnished  to  the Company by such Selling Shareholder and
stated to be specifically for use in connection with the offering of Registrable
Securities.

          1.7.3  Indemnification  Procedure.  Promptly  after  receipt  by  an
                 --------------------------
indemnified  party  under  this Section 1.7 of notice of the commencement of any
action  which  may  give  rise  to  a  claim for indemnification hereunder, such
indemnified  party  will, if a claim in respect thereof is to be made against an
indemnifying  party  under  this  Section  1.7, notify the indemnifying party in
writing  of  the  commencement  thereof and generally summarize such action. The
indemnifying  party  shall  have  the  right to participate in and to assume the
defense  of  such claim, and shall be entitled to select counsel for the defense
of  such  claim  with  the  approval of any parties entitled to indemnification,
which  approval  shall  not  be  unreasonably  withheld.  Notwithstanding  the
foregoing,  the  parties  entitled  to  indemnification  shall have the right to
employ  separate  counsel (reasonably satisfactory to the indemnifying party) to
participate  in  the  defense thereof, but the fees and expenses of such counsel
shall  be at the expense of such indemnified parties unless the named parties to
such  action  or  proceedings  'include  both  the  indemnifying  party  and the
indemnified parties and the indemnifying party or such indemnified parties shall
have been advised by counsel that there are one or more legal defenses available
to  the  indemnified  parties  which  are  different from or additional to those
available  to  the indemnifying party (in which case, if the indemnified parties
notify  the  indemnifying  party  in  writing that they elect to employ separate
counsel  at  the  reasonable expense of the indemnifying party, the indemnifying
party  shall  not  have  the  right  to  assume  the  defense  of such action or
proceeding  on  behalf of the indemnified parties, it being understood, however,
that  the  indemnifying  party  shall not, in connection with any such action or
proceeding  or separate or substantially similar or related action or proceeding
in  the  same  jurisdiction  arising  out  of  the  same  general allegations or
circumstances,  be  liable for the reasonable fees and expenses of more than one
separate counsel at any time for all indemnified parties, which counsel shall be
designated  in  writing  by  the  Shareholders  of a majority of the Registrable
Securities).

          1.7.4  Contribution.  If  the  indemnification  provided  for  in this
                 ------------
Section  1.7  from  an indemnifying party is unavailable to an indemnified party
hereunder  in  respect  to  any losses, claims, damages, liabilities or expenses
referred  to  herein,  then the indemnifying party, in lieu of indemnifying such
indemnified  party,  shall  contribute  to  the  amount  paid or payable by such
indemnified  party  as  a result of such losses, claims, damages, liabilities or
expenses  in  such proportion as is appropriate to reflect the relative fault of
the  Indemnifying  party and indemnified party in connection with the statements
or  omissions  which  result  in  such  losses,  claims, damages, liabilities or
expenses,  as well as any other relevant equitable considerations.  The relative
fault  of  such  indemnifying party and indemnified party shall be determined by
reference to, among other things, whether the untrue or alleged untrue statement
of  a material fact or the omission or alleged omission to state a material fact
relates  to information supplied by such indemnifying party or indemnified party
and  the  parties' relative intent, knowledge, access to information supplied by
such  indemnifying  party  or  indemnified  party  and opportunity to correct or
prevent  such statement or omission.  The amount paid or payable by a party as a
result  of  the  losses,  claims,  damages, liabilities and expenses referred to
above  shall be deemed to include any legal or other fees or expenses reasonably
incurred by such party in connection with investigating or defending any action,
suit,  proceeding  or  claim.

     2.     Covenants  of  the  Company.
            ---------------------------

 The  Company  agrees  to:

     (a)  Notify  the  holders  of  Registrable  Securities  included  in  a
Registration  Statement  of  the  issuance  by  the Commission of any stop order
suspending the effectiveness of such Registration Statement or the initiation of
any  proceedings for that purpose. The Company will make every reasonable effort
to  prevent  the issuance of any stop order and, if any stop order is issued, to
obtain  the  lifting  thereof  at  the  earliest  possible  time.

     (b)  If  the Common Stock is then listed on a national securities exchange,
use  its  best  efforts to cause the Registrable Securities to be listed on such
exchange.  If  the  Common  Stock  is  not  then listed on a national securities
exchange, use its commercially reasonable efforts to facilitate the reporting of
the  Registrable  Securities  on  NASDAQ.

     (c)  Take all other reasonable actions necessary to expedite and facilitate
disposition of the Registrable Securities by the holders thereof pursuant to the
Registration  Statement.

     (d)  With  a  view  to  making  available  to  the  holders  of Registrable
Securities the benefits of Rule 144 promulgated under the Securities Act and any
other  rule  or  regulation  of  the  Commission that may at any time permit the
Shareholders  to  sell  securities  of  the  Company  to  the  public  without
registration,  the  Company,  after  it has become obligated to file periodic or
other  reports  pursuant  to  Section  13  of  the  1934  Act  agrees  to:

(i)  file with the Commission in a timely manner all reports and other documents
required of the Company under the Securities Act and the Securities and Exchange
Act  of  1934  (the  "1934  Act");  and

     (ii)  furnish  to  each  holder of Shares, so long as such holder of Shares
owns  any  Shares, forthwith upon written request (a) a written statement by the
Company that it has complied with the reporting requirements of Rule 144 (at any
time  after 90 days after the effective date of the first registration statement
filed by the Company), the Securities Act and the 1934 Act (at any time after it
has  become  subject  to  such  reporting  requirements), (b) a copy of the most
recent  annual  or  quarterly  report  of the Company and such other reports and
documents  so  filed  by  the  Company  and (c) such other information as may be
reasonably  requested  and  as  is publicly available in availing the holders of
Shares  of any rule or regulation of the Commission which permits the selling of
any  such  securities  without  registration.

     (e)  Prior  to  the  filing  of the Registration Statement or any amendment
thereto  (whether  pre-effective  or post-effective), and prior to the filing of
any  prospectus  or  prospectus  supplement  related  thereto,  the Company will
provide each Selling Shareholder with copies of all pages thereto, if any, which
reference  such  Selling  Shareholder.

  3.     Miscellaneous.
         -------------

     (a)  Notices  required  or  permitted  to  be  given  hereunder shall be in
writing  and  shall be deemed to be sufficiently given when personally delivered
or  sent  by  registered mail, return receipt requested, addressed (i) if to the
Company,  at  1726  Medical  Blvd,  Suite 101, Naples, FL 34110 and (ii) if to a
Shareholder, at the address set forth in the Company's records, or at such other
address  as  each  such  party furnishes by notice given in accordance with this
Section  3(a);

     (b)  Failure  of  any  party  to  exercise  any  right or remedy under this
Agreement  or otherwise, or delay by a party in exercising such right or remedy,
will  not  operate  as a waiver thereof.  No waiver will be effective unless and
until  it  is  in  writing  and  signed  by  the  party  giving  the  waiver;

     (c)  Governing  Law;  Jurisdiction;  Jury Trial.  The corporate laws of the
State  of  Nevada  shall govern all issues concerning the relative rights of the
Company  and  its Shareholders. All other questions concerning the construction,
validity,  enforcement and interpretation of this Agreement shall be governed by
the  internal  laws of the State of Florida, without giving effect to any choice
of  law or conflict of law provision or rule (whether of the State of Florida or
any  other  jurisdictions)  that  would cause the application of the laws of any
jurisdictions  other  than  the State of Florida.  Each party hereby irrevocably
submits to the jurisdiction of the Circuit Court for Collier County, Florida and
the  United  States  District  Court  for the Middle District of Florida for the
adjudication  of  any  dispute  hereunder  or in connection herewith or with any
transaction  contemplated  hereby  or  discussed  herein, and hereby irrevocably
waives,  and  agrees  not to assert in any suit, action or proceeding, any claim
that  it  is  not personally subject to the jurisdiction of any such court, that
such  suit, action or proceeding is brought in an inconvenient forum or that the
venue  of  such  suit,  action  or  proceeding  is  improper.  EACH PARTY HEREBY
IRREVOCABLY  WAIVES  ANY  RIGHT  IT  MAY HAVE, AND AGREES NOT TO REQUEST, A JURY
TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR
ARISING  OUT  OF  THIS  AGREEMENT  OR  ANY  TRANSACTION  CONTEMPLATED  HEREBY.

     (d)  In  the  event  that  any  provision  of  this Agreement is invalid or
unenforceable  under any applicable or rule of law, then such provision shall be
deemed  inoperative  to  the  extent that it may conflict therewith and shall be
deemed  modified  to  conform  with  such statute or rule of law.  Any provision
hereof  which  may prove invalid or unenforceable under any law shall not affect
the  validity  or  enforceability  of  any  other  provision  hereof,

     (e)  This  Agreement  may be assigned by the Shareholders to any transferee
of  the  Shareholder's  Shares;

     (f)  This  Agreement  constitutes  the entire agreement between the parties
hereto  with  respect  to  the  subject  matter  hereof;  and

     (g)  This  Agreement  may  be executed in two or more counterparts, each of
which  when  so executed and delivered shall be deemed to be an original and all
of  which  together  shall  be  deemed  to  be  one  and  the  same  Agreement.

<PAGE>
     IN WITNESS WHEREOF, the Company has executed this Agreement for the benefit
of  the  Shareholders  by its duly authorized officer as of the date first above
written.

                                   NEOGENOMICS,  INC.

                                   By:____________________________
                                  Name:
                                  Title:    President

                                 MVP  3,  LP,  A  DELAWARE  LIMITED  PARTNERSHIP

                                  BY:  MEDICAL  VENTURE  PARTNERS,  LLC,
                                  A  DELAWARE  LIMITED LIABILITY
                                  COMPANY,  ITS  GENERAL  PARTNER

                                   By:____________________________
                                   Name:
                                   Title:

                                   _______________________________
                                        John  E.  Elliot

                                   _______________________________
                                        Steven  C.  Jones

                                   _______________________________
                                        Larry  R.  Kuhnert

                                   _______________________________
                                        Michael  T.  Dent,  M.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}]]